MY193591A - Standardised extract of labisia pumila for weight reduction and nano-formulation thereof - Google Patents

Standardised extract of labisia pumila for weight reduction and nano-formulation thereof

Info

Publication number
MY193591A
MY193591A MYPI2017000866A MYPI2017000866A MY193591A MY 193591 A MY193591 A MY 193591A MY PI2017000866 A MYPI2017000866 A MY PI2017000866A MY PI2017000866 A MYPI2017000866 A MY PI2017000866A MY 193591 A MY193591 A MY 193591A
Authority
MY
Malaysia
Prior art keywords
nano
weight
formulation
extract
weight reduction
Prior art date
Application number
MYPI2017000866A
Inventor
Ismail Zhari
Hooi Kheng Beh
Shahrul Ridzuan Hamil Mohd
Ghafar Gheniya
Ali Ahmad Saeed Mohammed
Hakeem Menon Abdul
Hashim Suzana
Original Assignee
Kementerian Pertanian & Ind Asas Tani
Medika Natura Sdn Bhd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kementerian Pertanian & Ind Asas Tani, Medika Natura Sdn Bhd filed Critical Kementerian Pertanian & Ind Asas Tani
Publication of MY193591A publication Critical patent/MY193591A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided an extract of Labisia pumila that comprises: gallic acid; caffeic acid; rutin; and one or more additional extract components, wherein on a dry weight basis: the weight/weight ratio of gallic acid to caffeic acid is from 10:1 to 75:1; the weight/weight ratio of gallic acid to rutin is from 10:1 to 50:1; and the weight/weight ratio of rutin to caffeic acid is from 1:0.3 to 1:4. There is also provided a nano-formulated liposome containing said extract and methods of preparing these compositions, as well as methods of using the same.
MYPI2017000866A 2014-12-08 2015-12-08 Standardised extract of labisia pumila for weight reduction and nano-formulation thereof MY193591A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MYPI2014703676 2014-12-08
MY2015050007 2015-02-26
PCT/MY2015/050152 WO2016093692A1 (en) 2014-12-08 2015-12-08 Standardised extract of labisia pumila for weight reduction and nanoformulation thereof

Publications (1)

Publication Number Publication Date
MY193591A true MY193591A (en) 2022-10-19

Family

ID=56107776

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017000866A MY193591A (en) 2014-12-08 2015-12-08 Standardised extract of labisia pumila for weight reduction and nano-formulation thereof

Country Status (2)

Country Link
MY (1) MY193591A (en)
WO (1) WO2016093692A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110090205B (en) * 2019-05-15 2021-03-23 蚌埠学院 Preparation method of chlorogenic acid lipid nanoparticle solid dispersion
US20230134529A1 (en) 2021-11-02 2023-05-04 Medika Natura Sdn. Bhd. Labisia pumila extract composition and its pharmaceutical formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147497A (en) * 2005-10-12 2012-12-14 Government Of Malaysia As Represented By The Ministry Of Science Technology And Innovation Malaysia Process for preparation of labisia pumila extract
MY151834A (en) * 2008-03-19 2014-07-14 Government Of Malaysia As Represented By The Ministry Of Science Technology And Innovation Malaysia A standardised aqueous extract of labisia pumila
MY170724A (en) * 2012-01-27 2019-08-27 Biotropics Malaysia Berhad Use of certain trioxygenated benzene derivatives in body fat management
MY156604A (en) * 2012-02-10 2016-03-15 Pharmaniaga Berhad Optimized extraction process for obtaining labisia pumila extract

Also Published As

Publication number Publication date
WO2016093692A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
MX2019003735A (en) Dilutable formulations of cannabinoids and processes for their preparation.
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2016016666A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016016143A (en) Substituted [1,2,4]triazole compounds.
MX2016011898A (en) Compositions of selenoorganic compounds and methods of use thereof.
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
PH12017500836A1 (en) Transdermal formulations
BR112016006048A8 (en) antimicrobial compositions
MX2020002123A (en) Ribociclib salts and solid state forms thereof.
MX2020006596A (en) Hydroxyisoxazolines and derivatives thereof.
PH12016502002A1 (en) Novel bacteriophage and composition comprising same
MX2017008390A (en) Alkoxysilane-functionalized and allophanate-functionalized urethanes.
EA033460B1 (en) Substituted [1,2,4]triazole compounds as fungicides
MX371128B (en) Dihydropyrimidine-2-one compounds and medicinal uses thereof.
MX2017016588A (en) Novel triterpene-glycosides as sweeteners or sweetener enhancer.
MX368582B (en) Gardenia extract for colouring the skin.
MX2021000508A (en) Dry, flowable sabadilla extract.
GEP20217236B (en) Composition comprising pentose and polyphenolic compound
CA3056612A1 (en) Analogs of deutetrabenazine, their preparation and use
MY193591A (en) Standardised extract of labisia pumila for weight reduction and nano-formulation thereof
MX2016003207A (en) Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation.
WO2015111004A3 (en) Improved process for the preparation of chlorophenyl trifluoroethanone
EP3694503A4 (en) Novel substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors